UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...

Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.

GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side ...

Hope surfaced this year in April, when Glaxo-SmithKline Pharmaceuticals Ltd launched Shingrix (or Zoster Vaccine Recombinant ... medical affairs director, GlaxoSmithKline. According to the API-Ipsos ...

Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...

The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.